Sophia Genetics and Realm IDx have signed a letter of intent to collaborate on next-generation sequencing research for cancer care.
The two firms plan to explore the further development of Realm IDx subsidiary Ambry Genetics' TumorNext-HRD (homologous recombination deficiency) ovarian cancer test as well as the possibility of combining Ambry's Variant Assessment database with Sophia Genetics' Sophia DDM platform for HRD detection.
As part of the collaboration, Sophia Genetics may use Ambry's lab for sequencing, Sophia said.
